ABERA BIOSCIENCE AB (8WK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ABERA BIOSCIENCE AB (8WK) has a cash flow conversion efficiency ratio of -0.317x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-7.44 Million ≈ $-8.70 Million USD) by net assets (€23.48 Million ≈ $27.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 8WK stock market capitalisation for the company's overall valuation and market capitalisation.
ABERA BIOSCIENCE AB - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how ABERA BIOSCIENCE AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ABERA BIOSCIENCE AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ABERA BIOSCIENCE AB ranked by their cash flow conversion efficiency. Explore 8WK cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lifestyle Global Enterprise
TWO:8066
|
0.102x |
|
Aelis Farma SA
PA:AELIS
|
-0.635x |
|
Australian Agricultural Projects Ltd
AU:AAP
|
0.124x |
|
Neuroscientific Biopharmaceuticals Ltd
AU:NSB
|
-0.029x |
|
Tong Hua Holding Public Company Limited
BK:TH
|
-0.006x |
|
Lode Resources Ltd
AU:LDR
|
-0.055x |
|
Yesil Yatirim Holding AS
IS:YESIL
|
0.000x |
|
Hanan Mor
TA:HNMR
|
0.062x |
Annual Cash Flow Conversion Efficiency for ABERA BIOSCIENCE AB (2022–2025)
The table below shows the annual cash flow conversion efficiency of ABERA BIOSCIENCE AB from 2022 to 2025. View ABERA BIOSCIENCE AB stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €19.29 Million ≈ $22.55 Million |
€-3.26 Million ≈ $-3.81 Million |
-0.169x | -638.52% |
| 2024-12-31 | €8.66 Million ≈ $10.12 Million |
€-198.00K ≈ $-231.48K |
-0.023x | +99.27% |
| 2023-12-31 | €5.66 Million ≈ $6.61 Million |
€-17.71 Million ≈ $-20.71 Million |
-3.132x | -166.86% |
| 2022-12-31 | €16.78 Million ≈ $19.62 Million |
€-19.69 Million ≈ $-23.02 Million |
-1.174x | -- |
About ABERA BIOSCIENCE AB
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead va… Read more